drugset / Trial / NCT05715606
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research
NaSequentialOpen-labelTreatment
Summary
A Study of Metabolically Armed CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma
Timeline
- Start
- 2023-02-10
- Primary completion
- 2025-02-01
- Completion
- 2025-05-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Metabolically Armed CD19 CAR-T cells | Cell therapy | — | Intravenous |